Ashland's pioneering epigenetic research, which began in 2015, has been validated by the 2024 Nobel Prize in Medicine awarded for the discovery of microRNAs. The company's work harnesses skin microRNA and plant small RNA to develop botanicals and peptides for skin benefits. Ashland has already commercialized dermostatyl IS biofunctional and elixiance biofunctional based on this science.
The company utilizes its proprietary Plant Small RNAs (PSR) technology to selectively extract vegetal small RNA and active phytocompounds from sustainably sourced plants. These include the Centifolia rose for rosaliss biofunctional, Lavandula Angustifolia for nightessence biofunctional, and Jasmine Grandiflorum for caressense biofunctional. This approach aims to improve skin health and prevent premature aging.
This alignment with Nobel-winning science reinforces Ashland's position as a leader in biofunctional innovation. It highlights the company's long-term investment in advanced research and its ability to translate scientific breakthroughs into commercial products for the personal care market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.